Nina Arakelyan

661 total citations
9 papers, 228 citations indexed

About

Nina Arakelyan is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nina Arakelyan has authored 9 papers receiving a total of 228 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nina Arakelyan's work include Lymphoma Diagnosis and Treatment (6 papers), Lung Cancer Treatments and Mutations (3 papers) and Viral-associated cancers and disorders (2 papers). Nina Arakelyan is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Lung Cancer Treatments and Mutations (3 papers) and Viral-associated cancers and disorders (2 papers). Nina Arakelyan collaborates with scholars based in France and United States. Nina Arakelyan's co-authors include Eugéniu Banu, Stéphane Oudard, Adela Banu, Annick Vieillefond, Frédéric Rolland, Jacques Médioni, Bernard Escudier, Brigitte Duclos, Franck Priou and Laure Fournier and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Nina Arakelyan

9 papers receiving 222 citations

Peers

Countries citing papers authored by Nina Arakelyan

Since Specialization

Citations

This map shows the geographic impact of Nina Arakelyan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nina Arakelyan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nina Arakelyan more than expected).

Fields of papers citing papers by Nina Arakelyan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nina Arakelyan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nina Arakelyan. The network helps show where Nina Arakelyan may publish in the future.

Co-authorship network of co-authors of Nina Arakelyan

This figure shows the co-authorship network connecting the top 25 collaborators of Nina Arakelyan. A scholar is included among the top collaborators of Nina Arakelyan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nina Arakelyan. Nina Arakelyan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B‐cell lymphoma in first relapse: results of the R‐NIMP GOELAMS study 2013 ·British Journal of Haematology ·Emmanuel Gyan, Diane Damotte, (unknown), Delphine Sénécal, Philippe Quittet, Aline Schmidt, Anne Banos, Steven Le Gouill, T. Lamy, Jean Fontan, Hervé Maisonneuve, Magda Alexis, François Dreyfus, Olivier Tournilhac, Kamel Laribi, Philippe Solal‐Céligny, Nina Arakelyan, Guillaume Cartron, Rémy Gressin, (unknown)	13
2	High-Output Cardiac Failure Revealing Primary Plasma Cell Leukemia 2013 ·SHILAP Revista de lepidopterología ·Driss Chaoui, B Gallet, Philippe Genet, (unknown), Ahmad Al Jijakli, Nina Arakelyan, (unknown), Laurent Sutton	2
3	Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation 2012 ·Leukemia & lymphoma ·Nina Arakelyan, Jean-Philippe Jaı̈s, (unknown), Philippe Colombat, Christian Berthou, B Desablens, Marie‐Pierre Moles‐Moreau, Thomas Gastinne, Philippe Quittet, Philippe Casassus, A. Le Mevel, C Ghandour, Josette Brière, P Colonna, Jean‐Marie Andrieu	1
4	Anaplastic Large Cell Lymphoma Occurring in an HIV-Positive Patient 2012 ·SHILAP Revista de lepidopterología ·Philippe Genet, Driss Chaoui, Virginie Masse, Ahmad Al Jijakli, Nina Arakelyan, Laurent Sutton	2
5	Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS 2011 ·Annals of Oncology ·Roch Houot, Steven Le Gouill, (unknown), Christiane Mounier, (unknown), (unknown), Krimo Bouabdallah, M Vigier, (unknown), Olivier Tournilhac, Nina Arakelyan, Philippe Rodon, Abderrazak El Yamani, Laurent Sutton, (unknown), David Assouline, Jean‐Luc Harousseau, Hervé Maisonneuve, Sylvie Caulet-Maugendre, Rémy Gressin	36
6	Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas 2010 ·Cancer ·Nina Arakelyan, Jean-Philippe Jaı̈s, Vincent Delwail, Josette Brière, Marie‐Pierre Moles‐Moreau, Delphine Sénécal, Christian Berthou, B Desablens, P Colonna, J Andrieu, (unknown)	10
7	Early versus late intensification for patients with high‐risk Hodgkin lymphoma—3 Cycles of intensive chemotherapy plus low‐dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation 2008 ·Cancer ·Nina Arakelyan, Christian Berthou, B Desablens, Sophie de Guibert, Vincent Delwail, Marie‐Pierre Moles, Philippe Quittet, Jean-Philippe Jaı̈s, P Colonna, Jean‐Marie Andrieu, (unknown)	22
8	Prospective Multicenter Phase II Study of Gemcitabine Plus Platinum Salt for Metastatic Collecting Duct Carcinoma: Results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) Study 2007 ·The Journal of Urology ·Stéphane Oudard, Eugéniu Banu, Annick Vieillefond, Laure Fournier, Franck Priou, Jacques Médioni, Adela Banu, Brigitte Duclos, Frédéric Rolland, Bernard Escudier, Nina Arakelyan, Stéphane Culine	134
9	Docetaxel versus mitoxantrone as first-line chemotherapy for hormone-refractory prostate cancer (HRPC) patients. A meta-analysis of 3-year overall survival results 2005 ·Journal of Clinical Oncology ·Stéphane Oudard, Eugéniu Banu, (unknown), F. Scotté, E. Lévy, J. Medioni, (unknown), J. Ayllón, Nina Arakelyan, Jean‐Marie Andrieu	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact